| |
Leadership
Board of Directors
Mark de Boer, Ph.D.
Chairman
Mark is currently a partner with Index Venture and has for the last 15 years worked for, managed and founded early-stage biopharmaceutical companies in the field of innovative novel biopharmaceuticals. He was the founder of PanGenetics BV, a successful therapeutic antibody company and he currently holds several board seats including PanGenetics, ProFibrix, CoMentis, and Molecular Partners. Mark’s research career was in the field of immuno-modulation and he is a pioneer in recombinant antibody technology. He teaches entrepreneurship in the Life Sciences at the Utrecht University in The Netherlands. Mark has an undergraduate degree in biochemistry and holds a Ph.D. in immunology from the University of Amsterdam.
Roman Fleck, Ph.D.
Index Ventures
Roman is a principal with Index Ventures. Prior to joining Index he worked for seven years at Boehringer Ingelheim Pharmaceuticals in Connecticut where he held roles of increasing responsibility in preclinical drug discovery and business development. Under his leadership several compounds were moved into clinical development. Roman received his Ph.D. in organic chemistry from the Massachusetts Institute of Technology where he performed research on catalytic antibodies. He also holds an MBA from New York University's Stern School of Business where he continues to serve as a mentor for aspiring entrepreneurs. Roman currently serves on the boards of GlycoVaxyn and Krisalis Life Sciences, and stays closely involved with Funxional Therapeutics, Normoxys, and OncoEthix.
Willem ‘Pim’ Stemmer, Ph.D.
Chief Executive Officer, Amunix
Pim has repeatedly invented technologies that have lead to successful companies and products. Pim is currently CEO and founder of Amunix, which has pioneered microprotein technology as well as XTEN technology. Previously, he founded Avidia after inventing it’s A-domain technology. In 1997, he founded Maxygen to commercialize the DNA Shuffling technology, now called Molecular Breeding, which lead to the founding of both Verdia and Codexis. Prior to Maxygen, Pim was a distinguished scientist at Affymax where he invented DNA shuffling technology. Before that, he worked on antibody fragment engineering at Hybritech. He completed post-doctoral work on phage display of random peptide libraries and antibody fragment expression in E. coli with Prof. Fred Blattner at the University of Wisconsin. Pim obtained his Ph.D. degree from the University of Wisconsin for his work on bacterial pili/fimbriae involved in host-pathogen interaction. Pim has over 60 research publications and over 80 issued patents. His portfolio of patents from Maxygen was ranked as the #1 portfolio in pharma/biotech for 2003 by M.I.T.'s Technology Review, and #2 in a review of the 150 largest pharma and biotech companies by The Wall Street Journal in 2006. Pim received the Doisy award, the Perlman award, the NASDAQ VCynic award and has given over 250 invited presentations.
Jeffrey L. Cleland, Ph.D.
Chief Executive Officer, Versartis
Jeff has 20 years of industry experience in research and development, including more than a decade at Genentech, Inc. He held executive management positions at BaroFold, Novacea, and Targesome, and has managed directly all aspects of pharmaceutical development and late-stage research. His experience in start-ups includes major roles in obtaining more than $70M of Series A through C venture capital as well as an exit via IPO. Jeff also runs his own pharmaceutical and biotechnology consulting group for numerous start-ups and venture firms. While at Genentech, Jeff served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as early work on Lucentis®, Avastin®, and Omnitarg®. He holds a BS degree in Chemical Engineering from the University of California, Davis and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. Jeff has authored more than 100 articles and four books, and holds several issued patents.
|
|
| |
|
|
